Beta-thalassemia
Beta-thalassemia (β-thalassemia) is an inherited blood disorder, a form of thalassemia resulting in variable outcomes ranging from clinically to severely anemic individuals. It is caused by reduced or absent synthesis of the beta chains of hemoglobin, the molecule that carries oxygen in the blood. Symptoms depend on the extent to which hemoglobin is deficient, and include , pallor, tiredness, enlargement of the , , and gallstones. In severe cases death ensues.
Underlined words are explained — tap any of them.
Symptoms — what it feels like
- ·, enlarged , abnormal bone structure
Causes — why it happens
- · in the gene
How it's found
- ·Blood smear, hemoglobin electrophoresis, iron & ferritin tests, DNA analysis
Prevention
- ·Preconception counseling
Treatment
- ·Blood transfusion, iron chelation, stem cell , gene therapy
Across the other high- (india) gene set (), 5 -'' are actually seen in South Asians () - many European-absent and still clinically 'uncertain'. For beta-thalassemia, that's a pool of computationally-damaging, India-relevant, clinically-unresolved variants no one has systematically characterised.
A study that would help: Take the South-Asian-observed, European-absent, ClinVar-uncertain in and triage them for beta-thalassemia: functional assays or family segregation to move them from 'uncertain' to a real call. Each reclassified is a usable diagnostic result.
The world's heaviest thalassemia burden — preventable, and genetically India-specific
India carries one of the largest beta-thalassemia burdens on Earth: about 3.7% of the population are carriers (up to 6.5% in Punjab), and an estimated 10,000+ children are born with thalassemia major every year. In the east — Bengal and Assam — HbE is the , with carrier rates reaching ~24% in parts of Assam.
This is a disease you prevent with carrier before conception, not one you cure. The is India-specific — IVS1-5, HbE and others — so screening panels must be tuned to Indian , not imported wholesale from Western references.
Carrier rates and major are well mapped. The gap is coverage and action: programs reach only a fraction of couples, and regional differences (HbE in the east, beta-thal in the north/west) need local .
A regionally-tuned carrier- rollout that measures how many at-risk couples are identified before conception — the intervention that actually lowers the birth , matched to each region's mix.
- Colah et al., 'Burden of thalassemia in India: the road map for control', 2017 ↗
- Prevalence of beta-thalassemia carriers in India: systematic review & meta-analysis, 2023 ↗
- D2I2 rare-pathogenic South-Asian scan (HBB)